CXCR4 antagonist
Motixafortide clinical trials
Answer
Motixafortide has 11 registered trials: 6 running, 3 completed, 1 stopped early. 2 posted results.
Trial registerClinicalTrials.gov and EU CTIS, read 2026-10-03
| Trial | Title | Status | Phase | Registered | Results |
|---|---|---|---|---|---|
| NCT04543071 Trial register | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | running, but no longer enrolling | - | 2020-09-09 | - |
| NCT06514508 Trial register | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | currently recruiting participants | - | 2024-07-23 | - |
| NCT06442761 Trial register | SCD Stem Cell Mobilization and Apheresis Using Motixafortide | currently recruiting participants | - | 2024-06-04 | - |
| 2024-511953-23-00 Trial register | A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL- | Not stated | 3 | - | - |
| NCT07392970 Trial register | Motixafortide for MRD Sensitization in AML | currently recruiting participants | - | 2026-02-06 | - |
| NCT07101445 Trial register | Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Pa | currently recruiting participants | - | 2025-08-03 | - |
| NCT06506461 Trial register | Gene Editing For Sickle Cell Disease | currently recruiting participants | - | 2024-07-17 | - |
| NCT06547112 Trial register | A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization | completed | - | 2024-08-09 | - |
| NCT05618301 Trial register | Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) | completed | - | 2022-11-16 | - |
| NCT05293171 Trial register | Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects | completed | - | 2022-03-24 | Posted |
| NCT03154827 Trial register | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | terminated before completion | - | 2017-05-14 | Posted |
Source: ClinicalTrials.gov and EU CTIS, read 2026-10-03. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.